On the basis of a double-blind randomized multicenter study, bradykinin B2 receptor antagonist was ineffective in improving the outcomes in patients with systemic inflammatory response syndrome and sepsis. This evidence concerns the gene BDKRB2 and systemic inflammatory response syndrome.